These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 21546048)

  • 1. Possible role of angiotensin-converting enzyme polymorphism on progression of hepatic fibrosis in chronic hepatitis C virus infection.
    Raslan HM; Amr KS; Elhosary YA; Ezzat WM; Abdullah NA; El-Batae HE
    Trans R Soc Trop Med Hyg; 2011 Jul; 105(7):396-400. PubMed ID: 21546048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Antiviral Therapy on Serum Activity of Angiotensin Converting Enzyme in Patients with Chronic Hepatitis C.
    Husic-Selimovic A; Sofic A; Huskic J; Bulja D
    Med Arch; 2016 Apr; 70(2):92-6. PubMed ID: 27147779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.
    Esmat G; El Raziky M; Elsharkawy A; Sabry D; Hassany M; Ahmed A; Assem N; El Kassas M; Doss W
    J Interferon Cytokine Res; 2015 Jan; 35(1):49-54. PubMed ID: 25061714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
    Bader el-Din NG; Abd el-Meguid M; Tabll AA; Anany MA; Esmat G; Zayed N; Helmy A; el-Zayady AR; Barakat A; el-Awady MK
    J Gastroenterol Hepatol; 2011 Jan; 26(1):55-62. PubMed ID: 21175794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
    Vezali E; Aghemo A; Colombo M
    Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
    Lange CM; Kutalik Z; Morikawa K; Bibert S; Cerny A; Dollenmaier G; Dufour JF; Gerlach TJ; Heim MH; Malinverni R; Müllhaupt B; Negro F; Moradpour D; Bochud PY;
    Hepatology; 2012 Apr; 55(4):1038-47. PubMed ID: 22095909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
    Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
    Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response.
    Floreani A; Cazzagon N; Boemo DG; Baldovin T; Baldo V; Egoue J; Antoniazzi S; Minola E
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):997-1003. PubMed ID: 21915057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
    Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
    Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
    Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.
    El Raziky M; Attia D; El Akel W; Shaker O; Khatab H; Abdo S; Elsharkawy A; Esmat G
    Arab J Gastroenterol; 2013 Sep; 14(3):94-8. PubMed ID: 24206736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients.
    Dai CY; Chuang WL; Hsieh MY; Huang JF; Lin YY; Chu PY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antiviral Res; 2010 Feb; 85(2):396-402. PubMed ID: 19931565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of polymorphisms in the first exon of mannose binding lectin gene (MBL2) in Brazilian patients with HCV infection.
    Segat L; Silva Vasconcelos LR; Montenegro de Melo F; Santos Silva B; Arraes LC; Moura P; Crovella S
    Clin Immunol; 2007 Jul; 124(1):13-7. PubMed ID: 17513174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C.
    Stättermayer AF; Rutter K; Beinhardt S; Wrba F; Scherzer TM; Strasser M; Hofer H; Steindl-Munda P; Trauner M; Ferenci P
    Liver Int; 2014 Mar; 34(3):388-95. PubMed ID: 23870067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ACE gene I/D polymorphism does not affect the susceptibility to or prognosis of PBC.
    Oruç N; Lamb J; Whitcomb DJ; Sass DA
    Turk J Gastroenterol; 2008 Dec; 19(4):250-3. PubMed ID: 19119484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
    Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.
    Butt AS; Mumtaz K; Aqeel I; Shah HA; Hamid S; Jafri W
    Trop Gastroenterol; 2009; 30(4):207-12. PubMed ID: 20426280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.